Boehringer Ingelheim has introduced LENZELTA, a new vaccine for dairy cows and heifers aimed at reducing both the incidence and severity of clinical mastitis. The product is becoming available in several EU countries from April 2026, adding a new prevention option in one of dairy farming’s most persistent health challenges. 

LENZELTA targets two major mastitis pathogens, Staphylococcus aureus and E. coli, and is designed to be given in two doses during the dry-off period. Boehringer Ingelheim says that schedule supports immunity through the high-risk period around calving, with protection lasting up to six months. 

The launch adds to a disease area where the pressure on farms is both biological and economic. Mastitis remains one of the most common diseases in dairy production, affecting udder health, milk quality and milk yield, while also increasing the risk of early culling. 

Boehringer Ingelheim is also highlighting the vaccine’s oil-free adjuvant and the availability of multiple vial sizes, positioning LENZELTA as a product that can fit more easily into routine herd-health programs. That practical angle may matter as dairy producers continue to look for prevention tools that support productivity as well as animal welfare.

For further information >>> Boehringer Ingelheim Animal Health.